Pharma

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

H. Lundbeck A/S' partner Teva Phamaceuticals Industries Ltd. announced that results from the ADAGIO trial, published online in The New England Journal of Medicine, demonstrated that Parkinson's disease patients receiving Azilect 1mg/day at the start of the study experienced superior benefit over 18 months compared with those who started the exact same treatment nine months later (delayed–start group)1. This finding is consistent with a possible disease–modifying effect for Azilect 1 mg/day.

Today in Research & Development...keeping you current

Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09

Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09

Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address